Screening for HIV: Review of the Evidence, Table 4. Studies Evaluating When to Initiate Antiretroviral Therapy in HIV-Infected Patients That Controlled for Lead-Time Bias

CD4 Cell Count at Which HAART Was Started, ×10⁹ cells/L	Clinical Progression or Mortality	Mortality (95% CI)	Source, Year (Reference)
0.501-0.750 vs. <0.500	Not reported	RR, 1.20 (0.17-8.53)	Palella, et al., 2003²¹⁰
0.351-0.500 vs. 0.200-0.350	Not reported	RR, 0.61 (0.22-1.67)	Palella, et al., 2003²¹⁰
0.351-0.500 vs. 0.200-0.350	HR,0.95 (P = 0.897)	Not reported	Ahdieh-Grant, et al., 2003²¹²
0.350-0.499 vs. <0.350	P = 0.21, log-rank test	P = 0.10, log-rank test	Sterling, et al., 2003²¹³
0.350 vs. <0.350	HR, 0.28 (0.12-0.68)	HR, 0.20 (0.07-0.52)	Opravil, et al., 2002²¹¹
0.350-0.499 vs. <0.200	HR, 0.37 (P = 0.003)	Not reported	Ahdieh-Grant, et al., 2003²¹²
0.201-0.350 vs. <200	Not reported	RR, 0.27 (0.14-0.55)	Palella, et al., 2003²¹⁰
0.201-0.350 vs. <200	HR,0.39 (P < 0.001)	Not reported	Ahdieh-Grant, et al., 2003²¹²

^aNotes: HAART = highly active antiretroviral therapy; HR = hazard ratio; RR = relative risk.